Guardant Health (NASDAQ: GH) reported Q4 EPS of ($0.69), $0.46 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $108 million versus the consensus estimate of $98.61 million.

GUIDANCE:

Guardant Health sees FY2022 revenue of $460-470 million, versus the consensus of $471 million.

For earnings history and earnings-related data on Guardant Health (GH) click here.